Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro

Antibody–drug conjugates, such as brentuximab vedotin (BTXv), are an innovative category of monoclonal antibodies. BTXv is bioconjugated via the chemical reduction of cysteine residues involved in disulfide bonds. Species of BTXv containing zero, two, four, six, or eight vedotin molecules per antibo...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2016-04, Vol.13 (4), p.1405-1412
Main Authors: Brachet, Guillaume, Respaud, Renaud, Arnoult, Christophe, Henriquet, Corinne, Dhommée, Christine, Viaud-Massuard, Marie-Claude, Heuze-Vourc’h, Nathalie, Joubert, Nicolas, Pugnière, Martine, Gouilleux-Gruart, Valérie
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Antibodies, Monoclonal - metabolism
Chromatography, Gel
Flow Cytometry
Histocompatibility Antigens Class I
Histocompatibility Antigens Class I - metabolism
Human health and pathology
Humans
Hydrophobic and Hydrophilic Interactions
Immunoconjugates
Immunoconjugates - metabolism
Life Sciences
Protein Binding
Receptors, Fc
Receptors, Fc - metabolism
Surface Plasmon Resonance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody–drug conjugates, such as brentuximab vedotin (BTXv), are an innovative category of monoclonal antibodies. BTXv is bioconjugated via the chemical reduction of cysteine residues involved in disulfide bonds. Species of BTXv containing zero, two, four, six, or eight vedotin molecules per antibody coexist in the stock solution. We investigated the influence of drug loading on the binding of the antibody to FcRn, a major determinant of antibody pharmacokinetics in humans. We developed a hydrophobic interaction chromatography (HIC) method for separating the different species present in the stock solution of BTXv, and we purified and characterized the collected species before use. We assessed the binding of these different species to FcRn in a cellular assay based on flow cytometry and surface plasmon resonance. HIC separated the different species of BTXv and allowed their collection at adequate levels of purity. Physicochemical characterization showed that species with higher levels of drug loading tended to form more aggregates. FcRn binding assays showed that the most conjugated species, particularly those with saturated loading, interacted more strongly than unconjugated BTXv with the FcRn.
ISSN:1543-8384
1543-8392
DOI:10.1021/acs.molpharmaceut.6b00082